|
 |
| home > epc > winter 2001 > the monoclonal anti-idiotype antibody aca 125 - a breakthrough for ovarian cancer |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
Q About 1.5 per cent of the female population suffer from ovarian
carcinoma - a tumour disease with a high mortality rate - in the
course of their lifetime. It is the fourth most common cause of
death from cancer in women. So why is the prognosis of this
malignant disease so bad?
A Due to the difficulties in making an early diagnosis of ovarian carcinoma, more than 70 per cent of the patients are only diagnosed at advanced stages and almost 20 per cent are already at stage four by the time of diagnosis. Accordingly, the prognosis for these tumours is comparatively poor. Although the prognosis for all stages regarding five-year survival has meanwhile increased, the relative five-year survival rate with advanced tumours is essentially lower. The number of lost years of life adds up to a total of about 100,000 years within the Federal Republic of Germany alone.
Q What approach is taken to the therapy of ovarian carcinoma
depending on the severity, for example a favourable prognosis,
but also rapid progression of large tumour masses and visceral
metastases?
A The aim of primary treatment of ovarian carcinoma is to firstly attain a favourable starting position for further treatment. The prognosis of the disease heavily depends on the post-operative tumour remains from the initial surgical operation. Subsequent treatment by means of chemotherapy - which must be carried out after the operation - is clearly dependent on the result of the surgical operation. Response rates of between 70 and 80 per cent are attained here. However, a smaller number of patients progress relatively quickly into a relapse situation, even after optimal initial therapy that appears to be resistant to chemotherapy and incurable.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Paediatric Clinical Trials
19-20 January 2009, Copthorne Tara Hotel, London, UK
More info >>
|
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
